On June 23, following its monthly meeting this week, the European Medicines Agency’s scientific committee, the CHMP, is expected to recommend approval of another biosimilar version of AbbVie Inc.’s blockbuster TNF-alpha inhibitor, Humira (adalimumab).
This is most likely to be Samsung Bioepis Co. Ltd.’s SB5, which was accepted for filing by the EMA...
Welcome to Scrip
Create an account to read this article
Already a subscriber?